Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenalidomide plus metronomic cyclophosphamide in relapsed/refractory classical Hodgkin lymphoma
2009-016588-12Phase 2Active
- Sponsor
- GOTEL
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and cyclophosphamide in Hodgkin lymphoma (HL), sponsored by GOTEL. Primary endpoint: Objective response rate. Started Apr 2010; status: active.
02
Drugs
lenalidomidecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2009-016588-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016588-12.